Author Question: A nurse educator is discussing how calcium channel blockers interact with the L-type calcium ... (Read 101 times)

dejastew · **on:** Jul 23, 2018

A nurse educator is discussing how calcium channel blockers interact with the L-type calcium channel.

The educator knows the students have understood the discussion when they state that L-type calcium channels are located in which location?
Note: Credit will be given only if all correct choices and no incorrect choices are selected.
Standard Text: Select all that apply.
1. The cardiovascular system
2. Neurons
3. Endocrine cells
4. Sensory cells
5. The gastrointestinal system

Question 2

A beta1-adrenergic antagonist drug has been added to the regimen of a client with angina pectoris who is taking amlodipine (Norvasc).

The nurse identifies which assessment finding as representing a goal of therapy related to a common mechanism of action of both drugs?
1. Peripheral edema
2. Decreased blood pressure
3. Flushing
4. Constipation

marict · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

Correct Answer: 1,2,3,4
Rationale 1: L-type calcium channels are widespread in the cardiovascular system.
Rationale 2: L-type calcium channels are located in neurons.
Rationale 3: L-type calcium channels are located in endocrine cells.
Rationale 4: L-type calcium channels are located in sensory cells.
Rationale 5: L-type calcium channels are not located in the gastrointestinal system.
Global Rationale: L-type calcium channels are widespread in the cardiovascular system, neurons, endocrine cells, and sensory cells. L-type calcium channels are not located in the gastrointestinal system.

Answer to Question 2

Correct Answer: 2
Rationale 1: Peripheral edema is an adverse effect associated with amlodipine (Norvasc) but not with beta1-adrenergic antagonist drugs.
Rationale 2: Both drugs have a therapeutic effect of decreasing calcium influx into vascular smooth muscle and lowering blood pressure.
Rationale 3: Flushing is a common but not significant consequence of peripheral vasodilation caused by amlodipine (Norvasc).
Rationale 4: Constipation is an adverse effect of calcium channel blockers, but is not associated with beta1-adrenergic blockers.
Global Rationale: Both drugs have a therapeutic effect of decreasing calcium influx into vascular smooth muscle and lowering blood pressure. Peripheral edema is an adverse effect associated with amlodipine (Norvasc) but not with beta1-adrenergic antagonist drugs. Flushing is a common but not significant consequence of peripheral vasodilation caused by amlodipine (Norvasc). Constipation is an adverse effect of calcium channel blockers, but is not associated with beta1-adrenergic blockers.